Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story
Crossref DOI link: https://doi.org/10.1007/s10529-015-1908-z
Published Online: 2015-07-07
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mor, Tsafrir S.
Funding for this research was provided by:
National Institutes of Health (P1 DA031340, U54 GM094599)
Text and Data Mining valid from 2015-07-07
Version of Record valid from 2015-07-07
Article History
Received: 6 May 2015
Accepted: 1 July 2015
First Online: 7 July 2015